Antimicrobial Treatment Duration in Sepsis and Serious Infections.
暂无分享,去创建一个
[1] Fang Zhang,et al. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use , 2020, JAMA network open.
[2] J. Rello,et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP) , 2019, Intensive Care Medicine.
[3] M. Hameed,et al. Comparison of 8 VS. 15 Days of Antibiotic Therapy for Ventilator-Associated Pneumonia in Adults: A Randomized Trial , 2019 .
[4] L. Pirofski,et al. Early Infectious Disease Consultation Is Associated With Lower Mortality in Patients With Severe Sepsis or Septic Shock Who Complete the 3-Hour Sepsis Treatment Bundle , 2019, Open forum infectious diseases.
[5] M. Kollef,et al. Pathogen-Negative Sepsis—An Opportunity for Antimicrobial Stewardship , 2019, Open forum infectious diseases.
[6] M. Fine,et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America , 2019, American journal of respiratory and critical care medicine.
[7] L. Rice,et al. Duration of Antibiotic Therapy: Shorter Is Better , 2019, Annals of Internal Medicine.
[8] Sameer S. Kadri,et al. Difficult-to-Treat Antibiotic-Resistant Gram-Negative Pathogens in the Intensive Care Unit: Epidemiology, Outcomes, and Treatment , 2019, Seminars in Respiratory and Critical Care Medicine.
[9] V. Chopra,et al. Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia , 2019, Annals of Internal Medicine.
[10] J. Powers,et al. Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis. , 2019, Chest.
[11] J. Lundgren,et al. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial , 2019, Trials.
[12] S. Cosgrove,et al. Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia , 2019, JAMA internal medicine.
[13] M. Kollef,et al. Duration of Exposure to Antipseudomonal β‐Lactam Antibiotics in the Critically Ill and Development of New Resistance , 2019, Pharmacotherapy.
[14] L. Leibovici,et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] Yi Zhang,et al. Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients , 2018, Mediators of inflammation.
[16] Rinaldo Bellomo,et al. Liberal Versus Restrictive Intravenous Fluid Therapy for Early Septic Shock: Rationale for a Randomized Trial. , 2018, Annals of emergency medicine.
[17] P. Malani,et al. Treatment Algorithms for Staphylococcal Bacteremia: Improving Clinical Care and Enhancing Antimicrobial Stewardship. , 2018, JAMA.
[18] J. S. Daly,et al. Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial , 2018, JAMA.
[19] L. Moldawer,et al. Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome , 2018, Front. Immunol..
[20] E. Lindsay. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock , 2018, The Journal of Emergency Medicine.
[21] B. Spellberg,et al. Busting the Myth of “Static vs Cidal”: A Systemic Literature Review , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Dustin L. Stwalley,et al. Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections , 2018, Open forum infectious diseases.
[23] B. Souweine,et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock , 2018, The New England journal of medicine.
[24] D. Cook,et al. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial , 2018, Trials.
[25] R. M. Pino,et al. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis , 2018 .
[26] R. Bellomo,et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock , 2018, The New England journal of medicine.
[27] S. Bozzette,et al. Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis* , 2017, Critical care medicine.
[28] J. Pérez-Simón,et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. , 2017, The Lancet. Haematology.
[29] Chunsheng Li,et al. Increased Expression of Programmed Cell Death‐1 in Regulatory T Cells of Patients with Severe Sepsis and Septic Shock: An Observational Clinical Study , 2017, Scandinavian journal of immunology.
[30] P. Torabi-Parizi,et al. Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection , 2017, American journal of respiratory and critical care medicine.
[31] C. Coopersmith,et al. Sepsis National Hospital Inpatient Quality Measure (SEP-1): Multistakeholder Work Group Recommendations for Appropriate Antibiotics for the Treatment of Sepsis. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] L. Scudeller,et al. Infectious Diseases Team for the Early Management of Severe Sepsis and Septic Shock in the Emergency Department , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Susan Gruber,et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014 , 2017, JAMA.
[34] E. Perencevich,et al. Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration Hospitals, 2003-2014 , 2017, JAMA internal medicine.
[35] G. Escobar,et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis , 2017, American journal of respiratory and critical care medicine.
[36] R. Wunderink,et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia , 2017, European Respiratory Journal.
[37] S. Lemeshow,et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis , 2017, The New England journal of medicine.
[38] Alan E. Jones,et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.
[39] C. Rhee. Using Procalcitonin to Guide Antibiotic Therapy , 2016, Open forum infectious diseases.
[40] Peggy Cruse,et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] A. Bilbao,et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. , 2016, JAMA internal medicine.
[42] B. Spellberg. The New Antibiotic Mantra-"Shorter Is Better". , 2016, JAMA internal medicine.
[43] L. Lagunes,et al. Current understanding in source control management in septic shock patients: a review. , 2016, Annals of translational medicine.
[44] N. Salahuddin,et al. Determinants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study , 2016, Critical care research and practice.
[45] J. Schwartz,et al. Impact of Infectious Diseases Consultation on Clinical Outcomes of Patients with Staphylococcus aureus Bacteremia in a Community Health System , 2016, Antimicrobial Agents and Chemotherapy.
[46] Tom Dormans,et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. , 2016, The Lancet. Infectious diseases.
[47] R. Hotchkiss,et al. Sepsis and septic shock , 2016, Nature Reviews Disease Primers.
[48] J. Timsit,et al. A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] T. van der Poll,et al. Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis. , 2016, JAMA.
[50] P. Gruber,et al. Severe infections in neutropenic patients , 2015, Current opinion in critical care.
[51] Yingying Yan,et al. Effect of critical care pharmacist's intervention on medication errors: A systematic review and meta-analysis of observational studies. , 2015, Journal of critical care.
[52] S. Seo,et al. Antimicrobial de-escalation in septic cancer patients: is it safe to back down? , 2015, Intensive Care Medicine.
[53] Vance G. Fowler,et al. Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management , 2015, Clinical Microbiology Reviews.
[54] P. Lipsett,et al. Trial of short-course antimicrobial therapy for intraabdominal infection. , 2015, The New England journal of medicine.
[55] Derek Bell,et al. Trial of early, goal-directed resuscitation for septic shock. , 2015, The New England journal of medicine.
[56] M. Dupon,et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial , 2015, The Lancet.
[57] M. Bailey,et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. , 2014, American journal of respiratory and critical care medicine.
[58] Michael Bailey,et al. Goal-directed resuscitation for patients with early septic shock. , 2014, The New England journal of medicine.
[59] G. Moran,et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. , 2014, The Lancet. Infectious diseases.
[60] Amber E Barnato,et al. A randomized trial of protocol-based care for early septic shock. , 2014, The New England journal of medicine.
[61] R. Hotchkiss,et al. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.
[62] L. Leibovici,et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. , 2013, The Journal of antimicrobial chemotherapy.
[63] B. Carr,et al. Benchmarking the Incidence and Mortality of Severe Sepsis in the United States* , 2013, Critical care medicine.
[64] J. Vincent,et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.
[65] T. Fleming,et al. Noninferiority trials: clinical understandings and misunderstandings. , 2013, Clinical investigation.
[66] R. Hotchkiss,et al. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. , 2013, The Lancet. Infectious diseases.
[67] Anita F. Das,et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. , 2013, JAMA.
[68] A. Lannergård,et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial , 2012, The Lancet.
[69] Sanjay Kaul,et al. Non-inferiority study design: lessons to be learned from cardiovascular trials. , 2012, European heart journal.
[70] Andrew Rhodes,et al. Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.
[71] R. Hotchkiss,et al. Immunosuppression in patients who die of sepsis and multiple organ failure. , 2011, JAMA.
[72] A. Akram,et al. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia--a propensity-adjusted analysis. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[73] M. Bauer,et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate , 2011, Critical care.
[74] V. Yu,et al. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. , 2011, Chest.
[75] Leonard Leibovici,et al. Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis , 2010, Antimicrobial Agents and Chemotherapy.
[76] J. Horton,et al. Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[77] F. Tubach,et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.
[78] J. Ramirez,et al. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia , 2009, European Respiratory Journal.
[79] Anand Kumar,et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. , 2009, Chest.
[80] J. Marshall,et al. Principles of source control in the management of sepsis. , 2009, Critical care clinics.
[81] M. Dünser,et al. Macroscopic Postmortem Findings in 235 Surgical Intensive Care Patients with Sepsis , 2009, Anesthesia and analgesia.
[82] C. Chung,et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis , 2009, Proceedings of the National Academy of Sciences.
[83] A. Limaye,et al. Reactivation of Cytomegalovirus Infection in Critically Ill Immunocompetent Patients—Reply , 2008 .
[84] 古谷 良輔,et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.
[85] C. Klug. A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days with Ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis , 2008 .
[86] Sanjay Kaul,et al. Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials , 2006, Annals of Internal Medicine.
[87] K. Wood,et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.
[88] S. Opal,et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. , 2006, The Journal of infectious diseases.
[89] Michel Wolff,et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.
[90] M. Singer,et al. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. , 2003, The Journal of antimicrobial chemotherapy.
[91] C. Woods,et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. , 2003, Archives of internal medicine.
[92] Leon G Smith,et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[93] J Ean,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.
[94] G Sherman,et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.
[95] A. Schaeffer,et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women , 1999 .
[96] D. Bates,et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. , 1999, JAMA.
[97] J. Bartlett,et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[98] D. Pittet,et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.
[99] I. Gurevich. Staphylococcus aureus bacteremia. , 1987, American journal of infection control.
[100] C. M. Nolan,et al. Staphylococcus aureus bacteremia: Current clinical patterns , 1976 .
[101] Various Combinations of Isoniazid with Streptomycin or with P.A.S. in the Treatment of Pulmonary Tuberculosis , 1955, British medical journal.
[102] B. Moynihan. Abstracts of the Arris and Gale Lectures on the Anatomy and Pathology of the Rarer Forms of Hernia , 1900 .
[103] J. Parrillo,et al. Culture-Negative Septic Shock Compared With Culture-Positive Septic Shock: A Retrospective Cohort Study , 2018, Critical care medicine.
[104] R. Sawyer. Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection. , 2018, The New England journal of medicine.
[105] M. Levy,et al. Impact of Source Control in Patients With Severe Sepsis and Septic Shock* , 2017, Critical care medicine.
[106] M. Rosengart,et al. The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. , 2017, Surgical infections.
[107] Lawrence P. Martinelli,et al. Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[108] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[109] K. Sepkowitz,et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[110] A. Fisher,et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. , 2008, Urology.